{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibqag225dmjawvvkaqd57jczkybn4ktzwtjqc4xwtbw6zsszgyh34",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfmpyheyu542"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreif3dhr3r5v5nzxhirrld36pqdnwbbbkjdmnswxebpdlszuk43suze"
    },
    "mimeType": "image/jpeg",
    "size": 104425
  },
  "path": "/2026/02/24/biotech-news-novo-nordisk-triple-g-obesity-results/?utm_campaign=rss",
  "publishedAt": "2026-02-24T14:30:06.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "Fresh off a failed trial that sent its shares plummeting, Novo Nordisk said that one of its experimental obesity drugs helped patients lose nearly 20% of their weight after 24 weeks…",
  "title": "STAT+: Novo reports ‘triple G’ obesity drug study results",
  "updatedAt": "2026-02-24T14:32:05.000Z"
}